Table 3 Tumour and treatment characteristics for patients with local failure (n = 9)
From: Spinal radiosurgery - efficacy and safety after prior conventional radiotherapy
No. | Tumour type | Location | Volume (cc) | Prescription Dose (Gy) SRS | Isodose (%) SRS | Time (months) RTX to SRS | Prior RTX Dose nBED Gy 2/2 |
|---|---|---|---|---|---|---|---|
1 | RCC | T11 | 93.3 | 16 | 65 | 21.7 | 42,8 |
2 | RCC | L3 | 134.2 | 19 | 55 | 8.8 | 40 |
3 | Chordoma | L2 | 39.7 | 22 | 65 | 12.4 | 40 |
4 | Prostate | T11 | 89.8 | 18 | 65 | 2.8 | 45 |
5 | Melanoma | C7 | 17.7 | 17 | 65 | 4.3 | 33.6 |
6 | Sarcoma | L4 | 56.3 | 20 | 70 | 2 | 44 |
7 | Breast | L3 | 37.6 | 20 | 70 | 28.8 | 42.8 |
8 | MPNST | T1 | 26.8 | 14.5 | 70 | 5.8 | 42.8 |
9 | RCC | T9 | 49.9 | 22 | 70 | 13.9 | 42.8 |
| Â | Median | - | 49.9 | 19 | 65 | 8.8 | 42.8 |
| Â | Mean | - | 60.6 | 18.8 | 66 | 11.2 | 41.6 |
| Â | Range | - | 18-134 | 14.5-22 | 55-70 | 2-28.8 | 33.6-45 |